Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Chimeric/humanized hybrid (mouse/human) |
| Target | CD19 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4850H7485N1305O1487S35 |
| Molar mass | 108989.98 g·mol−1 |
This drug was developed by Janssen Global Services.[3]
References
edit- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ^ Izhak L, Cullen DE, Elgawly M, Luistro L, Johnson S, Bald J, Sasser AK, Balasubramanian S (July 2017). "Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models". Cancer Research. doi:10.1158/1538-7445.AM2017-3636.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Duvortuxizumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |